中國生物科技服務(08037.HK)訂意向書擬600萬美元出售附屬增利控股
中國生物科技服務(08037.HK)公布,於6月27日,公司與中國新證財經資訊有限公司(買方)訂立一項無法律約束力的意向書。公司擬出售而買方擬收購公司全資附屬公司增利控股的全部已發行股本,現金代價為600萬美元(相當於約4,680萬港元),惟須出具估值報告及盡職調查報告,其確認建議買賣增利的價值。
公司認為,可能出售事項將為公司提供機會,可透過出售增利的全部已發行股份將其於Broncus的投資變現,並將讓集團可專注於核心業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.